Home / Companies / Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
How funds and institutional managers reported voting their shares, year to 30 June 2026
- Filers reporting
- 64year to 30 June 2026
- Against management on pay
- 0.0%0 of 1 reporting filers
- Same, by reported shares
- 0.0%shares reported on Form N-PX
- Meetings on file
- 3across 1 season
foragainstabstain, withhold or otheramber tick: the portion cast against management
For the year to 30 June 2026, 64 funds and managers listed Jiangsu Hengrui Pharmaceuticals Co., Ltd. in their Form N-PX filings (3 meetings).
On the advisory vote on executive pay, 0 of the 1 filers that reported a position voted against management (0.0%), 6.6 percentage points below the median company on this site (6.6%). By reported shares the figure is 0.0% (median 2.9%). These are shares of the filers reporting on Form N-PX, not of all votes cast at the meeting.
Meetings
| Meeting date | Season | Filers reporting | Items | Against management on pay |
|---|---|---|---|---|
| 16 Apr 2026 | year to 30 June 2026 | 49 | 9 | 0.0% |
| 31 Dec 2025 | year to 30 June 2026 | 54 | 2 | not reported |
| 16 Sep 2025 | year to 30 June 2026 | 48 | 4 | not reported |
Meetings with 20 or more reporting filers have their own page with every item. Dates are as filers typed them; dates up to three days apart are treated as one meeting.
Say-on-pay: this company and the median
| year to 30 June 2026 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Median company |
|---|---|---|
| Reporting filers voting against management | 0.0% | 6.6% |
| Reported shares voted against management | 0.0% | 2.9% |
Among filers reporting on Form N-PX. The median is over 3,799 companies with a say-on-pay item reported by 20 or more filers.
How the largest families voted
Meeting of 31 Dec 2025: say-on-pay and each shareholder proposal that could be told apart.
None of the families tracked on this site reported a position on these items.
By season
| Season | Filers reporting | Against management on pay, filers | By reported shares | Say-on-pay split |
|---|---|---|---|---|
| year to 30 June 2026 | 64 | 0.0% | 0.0% |
Category mix
Share of the vote records reported for this company, by the category filers chose.
| Category | Vote records | Share |
|---|---|---|
| DIRECTOR ELECTIONS | 836 | 41.1% |
| CORPORATE GOVERNANCE | 521 | 25.6% |
| COMPENSATION | 329 | 16.2% |
| CAPITAL STRUCTURE | 171 | 8.4% |
| AUDIT-RELATED | 148 | 7.3% |
| OTHER | 28 | 1.4% |
| SECTION 14A SAY-ON-PAY VOTES | 3 | 0.1% |
Questions
How did large funds vote at Jiangsu Hengrui Pharmaceuticals Co., Ltd.?
For the year to 30 June 2026, 1 Form N-PX filers reported a say-on-pay vote at Jiangsu Hengrui Pharmaceuticals Co., Ltd.; 0 voted against management (0.0%). The table on this page lists the position of each of the largest fund families on say-on-pay and on each shareholder proposal that could be told apart in the filings.
Were there shareholder proposals at Jiangsu Hengrui Pharmaceuticals Co., Ltd.?
No proposal from security holders was reported by enough filers to be shown for the year to 30 June 2026.
Is this the meeting result?
No. The figures are shares of the funds and managers that file Form N-PX, and of the shares they reported. Holders that do not file the form (individuals, most foreign investors, insiders) are not included, so the split here can differ widely from the certified result, which Jiangsu Hengrui Pharmaceuticals Co., Ltd. reports on Form 8-K.
Where does the data come from?
From Form N-PX filings on the SEC's EDGAR system, grouped by company. Filers type company names and meeting dates themselves; this site groups spellings of the same company and folds meeting dates up to three days apart. Data runs through 23 Sep 2026; the median compares 3,799 companies.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list Jiangsu Hengrui Pharmaceuticals Co., Ltd., grouped by company. The name is the most common spelling among filers; the ticker and SEC company number come from the SEC company tickers file, matched on the exact name. Not verified by the SEC. Filings read through 23 Sep 2026; page built 26 Sep 2026.